Ab­bas Hus­sain swings from top GSK phar­ma post to pow­er­house Chi­nese pri­vate eq­ui­ty play­er C-Bridge

Near the be­gin­ning of this year Ab­bas Hus­sain an­nounced plans to leave his role as Glax­o­SmithK­line’s phar­ma chief, hand­ing over the job to Luke Miels as new CEO Em­ma Walm­s­ley be­gan to as­sem­ble her own top team. And now Hus­sain has land­ed at C-Bridge Cap­i­tal, a pow­er­house Chi­nese pri­vate eq­ui­ty group which has in­vest­ed heav­i­ly in some promi­nent Asian biotechs.

Hus­sain spent eight years at GSK, build­ing the phar­ma gi­ant in­to the lead vol­ume op­er­a­tion in the drug in­dus­try and rolling out a quo­ta-free sales mod­el in dozens of coun­tries around the world. He start­ed as emerg­ing mar­kets chief, with a big role in clean­ing up a bribery scan­dal in Chi­na capped with a $500 mil­lion fine.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER